Core Business
New Drug R&D
Lumosa Therapeutics
Lumosa Therapeutics (Stock code: 6535.TW) is the "new drug development harbor in Taiwan," where scientific innovation meets visionary expertise. Our core competence lies in accelerating early-stage new drug introduction, optimizing development strategies, and fostering global licensing opportunities. Notably, LT1001, our long-acting analgesic injection, has gained marketing approvals in Taiwan, Singapore, Thailand, Malaysia and Ukraine, while LT3001's phase 2 trials for acute ischemic stroke treatment progress. Embracing our position as an international pharmaceutical R&D leader, Lumosa forges strategic alliances to minimize risks, accelerate product marketing, and elevate the standards of new drug development.
Taiwan
Investment time | 2011 |
Incubation Successes | Center Ventures helped launch Lumosa Therapeutics Co., Ltd. with the merge of SunTen Phytotech Co., Ltd., Cheng Pang Biopharma Company, and BroadCan Company. It introduced experienced operation teams to bring operational synergies, such as adjusting product development strategies and operational focus, as well as accelerating product development timeline. Center Ventures is actively integrating relevant resources to support corporate decision-making between Lumosa and TPG Biologics, enriching Lumosa’s product pipeline with both small and large molecule novel drugs while maximizing investment benefits. |
Milestones |
|